Midsized Biotechs Strike MFN Drug Pricing Deals

Nine midsize pharmaceutical manufacturers have agreed to price outpatient drugs for state Medicaid programs in line with what they charge in other developed countries, the White House announced today,¹ extending the administration’s Most Favored Nation (MFN) drug pricing campaign beyond the large drugmakers that have so far signed on to a tier of drugmakers that had largely sat outside these earlier deals.²